Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Grant | $40,000 | 1 | 94.3% |
| Food and Beverage | $1,591 | 34 | 3.7% |
| Travel and Lodging | $838.24 | 3 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $40,077 | 3 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,138 | 9 | $0 (2020) |
| AbbVie, Inc. | $327.36 | 3 | $0 (2017) |
| Valeant Pharmaceuticals North America LLC | $198.51 | 5 | $0 (2017) |
| Shire North American Group Inc | $138.27 | 4 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $124.99 | 1 | $0 (2022) |
| UCB, Inc. | $115.14 | 1 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $113.71 | 1 | $0 (2017) |
| Prometheus Laboratories Inc. | $81.91 | 4 | $0 (2017) |
| Janssen Biotech, Inc. | $49.64 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $150.18 | 2 | AstraZeneca Pharmaceuticals LP ($124.99) |
| 2021 | $12.99 | 1 | CSL Behring ($12.99) |
| 2020 | $1,068 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($1,068) |
| 2018 | $40,147 | 5 | PFIZER INC. ($40,077) |
| 2017 | $1,051 | 23 | AbbVie, Inc. ($327.36) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/18/2022 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 05/30/2022 | Medtronic, Inc. | VENASEAL (Device) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: EndoVenous Therapies | ||||||
| 09/20/2021 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: Immunology | ||||||
| 02/21/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $465.11 | General |
| 02/21/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $253.13 | General |
| 02/21/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 02/21/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $120.00 | General |
| 02/21/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $74.99 | General |
| 02/21/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $14.99 | General |
| 02/21/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $14.99 | General |
| 12/14/2018 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $72.78 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/01/2018 | Pfizer Inc. | — | Grant | Cash or cash equivalent | $40,000.00 | General |
| 06/03/2018 | Pfizer Inc. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $4.70 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/15/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Lower GI | ||||||
| 01/19/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Food and Beverage | In-kind items and services | $44.44 | General |
| Category: Lower GI | ||||||
| 12/13/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $120.92 | General |
| 12/13/2017 | Takeda Pharmaceuticals America, Inc. | Entyvio (Biological) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Lower GI | ||||||
| 12/01/2017 | Takeda Pharmaceuticals America, Inc. | Entyvio (Biological) | Food and Beverage | In-kind items and services | $10.28 | General |
| Category: Lower GI | ||||||
| 11/28/2017 | Valeant Pharmaceuticals North America LLC | RELISTOR ORAL (Drug), XIFAXANIBSD | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/21/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/07/2017 | AbbVie, Inc. | Viekira (Drug) | Food and Beverage | In-kind items and services | $118.59 | General |
| Category: Virology | ||||||
| 10/26/2017 | Shire North American Group Inc | GATTEX (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/16/2017 | Shire North American Group Inc | GATTEX (Drug) | Food and Beverage | In-kind items and services | $84.14 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/09/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/28/2017 | Janssen Scientific Affairs, LLC | STELARA (Biological), REMICADE | Food and Beverage | In-kind items and services | $113.71 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 12 | 21 | $9,030 | $1,643 |
| 2022 | 1 | 13 | 23 | $9,890 | $1,640 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 21 | $9,030 | $1,643 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 13 | 23 | $9,890 | $1,640 | 16.6% |
About Mark Salem
Mark Salem is a Gastroenterology healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2012. The National Provider Identifier (NPI) number assigned to this provider is 1821356254.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Salem has received a total of $42,429 in payments from pharmaceutical and medical device companies, with $150.18 received in 2022. These payments were reported across 38 transactions from 13 companies. The most common payment nature is "Grant" ($40,000).
As a Medicare-enrolled provider, Salem has provided services to 25 Medicare beneficiaries, totaling 44 services with total Medicare billing of $3,283. Data is available for 2 years (2022–2023), covering 2 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Orange, CA
- Active Since 04/23/2012
- Last Updated 02/04/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1821356254
Products in Payments
- Viekira (Drug) $206.44
- XIFAXAN (Drug) $168.67
- STELARA (Biological) $163.35
- GATTEX (Drug) $138.27
- SAPHNELO (Biological) $124.99
- Cimzia (Drug) $115.14
- Entyvio (Biological) $95.64
- XELJANZ (Drug) $77.48
- RELISTOR ORAL (Drug) $29.84
- VENASEAL (Device) $25.19
- Hizentra (Biological) $12.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Orange
C Gregory Albers, Md, MD
Gastroenterology — Payments: $645,882
Dr. Jason Samarasena, M.d, M.D
Gastroenterology — Payments: $317,485
Ke-Qin Hu, Md, MD
Gastroenterology — Payments: $298,529
Dr. Alaa Abousaif, Md, MD
Gastroenterology — Payments: $181,165
Dr. Usman Rahim, M.d, M.D
Gastroenterology — Payments: $57,201
Christopher Paiji, Md, MD
Gastroenterology — Payments: $53,765